229000.KQ
Price:
$1728
Market Cap:
$40.48B
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was founded in 2011 and is headquartered in Seoul, South Korea.
Industry
Medical - Specialties
IPO Date
2015-10-27
Stock Exchange
KOE
Ticker
229000.KQ
According to Gencurix, Inc.’s latest financial reports and current stock price. The company's current ROE is -57.56%. This represents a change of 281.51% compared to the average of -15.09% of the last 4 quarters.
The mean historical ROE of Gencurix, Inc. over the last ten years is -682.64%. The current -57.56% ROE has changed -91.57% with respect to the historical average. Over the past ten years (40 quarters), 229000.KQ's ROE was at its highest in in the December 2020 quarter at 66.73%. The ROE was at its lowest in in the December 2019 quarter at -3108.86%.
Average
-682.64%
Median
-108.47%
Minimum
-5904.25%
Maximum
62.03%
Discovering the peaks and valleys of Gencurix, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 9.31%
Maximum Annual ROE = 62.03%
Minimum Annual Increase = -280.36%
Minimum Annual ROE = -5904.25%
| Year | ROE | Change |
|---|---|---|
| 2025 | -45.12% | 62.06% |
| 2024 | -27.84% | -80.08% |
| 2023 | -139.81% | -63.20% |
| 2022 | -379.86% | 239.55% |
| 2021 | -111.87% | -280.36% |
| 2020 | 62.03% | -101.05% |
| 2019 | -5904.25% | 9.31% |
| 2018 | -62.74% | -41.07% |
| 2017 | -106.46% | -3.64% |
| 2016 | -110.48% | 83.19% |
The current ROE of Gencurix, Inc. (229000.KQ) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-70.92%
5-year avg
-140.90%
10-year avg
-682.64%
Gencurix, Inc.’s ROE is greater than Xcell Therapeutics, Inc. (-224.54%), less than Hass (-0.35%), greater than IVIM Technology (-9.90%), greater than BCWORLD PHARM. Co., Ltd. (-4.08%), greater than LAMEDITECH Co., Ltd. (-116.23%), less than Tdspharm (12.06%),
| Company | ROE | Market cap |
|---|---|---|
| -224.54% | $21.29B | |
| -0.35% | $39.05B | |
| -9.90% | $42.86B | |
| -4.08% | $30.87B | |
| -116.23% | $25.53B | |
| 12.06% | $32.21B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gencurix, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gencurix, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Gencurix, Inc.'s ROE?
How is the ROE calculated for Gencurix, Inc. (229000.KQ)?
What is the highest ROE for Gencurix, Inc. (229000.KQ)?
What is the 3-year average ROE for Gencurix, Inc. (229000.KQ)?
What is the 5-year average ROE for Gencurix, Inc. (229000.KQ)?
How does the current ROE for Gencurix, Inc. (229000.KQ) compare to its historical average?